JAMA Surg:结肠癌手术部位感染风险分层意义重大

2017-09-01 吴星 环球医学

2017年7月,发表在《JAMA Surg》的一项由美国科学家进行的研究考察了结肠癌中,手术部位感染的风险分层的意义。



2017年7月,发表在《JAMA Surg》的一项由美国科学家进行的研究考察了结肠癌中,手术部位感染的风险分层的意义。

重要性:手术部位感染(SSIs)对于手术质量的改善和绩效薪酬支付指标而言非常重要。为了预防或降低SSIs,已经使用了多种方法,带给患者和卫生保健预算沉重的负担。结肠癌手术也不例外。

目的:基于基线和手术特征确定风险分层评分。

设计、地点和参与者:这项回顾性队列研究纳入2004年至2014年在麻省总医院手术治疗结肠癌的全部患者(n=1481)。

主要结局和测量指标:在风险评分中,比较和复合基于基线和围手术期因素的分层SSI的发生率。

结果:在1481例参与者中,90例(6.1%)发生SSI。中位(IQR)年龄为66.9(55.9~78.1)岁。吸烟者(7.4% vs 4.8%;P=0.04)、酗酒者(10.6% vs 5.7%;P=0.04)、2型糖尿病患者(8.8% vs 5.5%;P=0.046)和肥胖患者(11.7% vs 4.0%;P<0.001)的手术部位感染率显着较高。手术持续时间超过140分钟(7.5% vs 5.0%;P=0.05)和非腹腔镜法(仅在临床上显着,6.7% vs 4.1%;P=0.07)患者的手术部位感染率也较高。作为复合评分,这些风险因素也与手术部位感染率增加相关(P<0.001)。有1个或更少风险因素的患者(n=427)的手术部位感染率为2.3%,相当于相对风险0.4(95% CI,0.16~0.57;P<0.001);有2个风险因素的患者(n=445)的手术部位感染率为5.2%(相对风险,0.78;95% CI,0.49~1.22;P=0.27);有3个风险因素的患者(n=384)的手术部位感染率为7.8%(相对风险,1.38;95% CI,0.91~2.11;P=0.13);有4个或更多风险因素的患者(n=198)的手术部位感染率为13.6%(相对风险,2.71;95% CI,1.77~4.12;P<0.001)。

结论和相关性:使用易获取的特征来通过SSI风险给患者分层,并确定术后住院期间处于风险的患者,SSI风险评估因素提供了简单的工具。因此,它可用于对高风险患者展开潜在频繁集中监测和更积极的预防措施。

原始出处:

Amri R, et al. Risk Stratification for Surgical Site Infections in Colon Cancer. JAMA Surg. 2017 Jul 1;152(7):686-690. doi: 10.1001/jamasurg.2017.0505.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1360961, encodeId=51a91360961c4, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370533, encodeId=c7e213e05338e, content=<a href='/topic/show?id=00505450e5f' target=_blank style='color:#2F92EE;'>#手术部位感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54507, encryptionId=00505450e5f, topicName=手术部位感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239482, encodeId=01f223948227, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Fri Sep 01 23:11:36 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239424, encodeId=c71823942475, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Sep 01 21:11:31 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1360961, encodeId=51a91360961c4, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370533, encodeId=c7e213e05338e, content=<a href='/topic/show?id=00505450e5f' target=_blank style='color:#2F92EE;'>#手术部位感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54507, encryptionId=00505450e5f, topicName=手术部位感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239482, encodeId=01f223948227, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Fri Sep 01 23:11:36 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239424, encodeId=c71823942475, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Sep 01 21:11:31 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1360961, encodeId=51a91360961c4, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370533, encodeId=c7e213e05338e, content=<a href='/topic/show?id=00505450e5f' target=_blank style='color:#2F92EE;'>#手术部位感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54507, encryptionId=00505450e5f, topicName=手术部位感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239482, encodeId=01f223948227, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Fri Sep 01 23:11:36 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239424, encodeId=c71823942475, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Sep 01 21:11:31 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 189****7206

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1360961, encodeId=51a91360961c4, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370533, encodeId=c7e213e05338e, content=<a href='/topic/show?id=00505450e5f' target=_blank style='color:#2F92EE;'>#手术部位感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54507, encryptionId=00505450e5f, topicName=手术部位感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sun Sep 03 11:07:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239482, encodeId=01f223948227, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Fri Sep 01 23:11:36 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239424, encodeId=c71823942475, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Sep 01 21:11:31 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 changjiu

    学习了.谢谢

    0

相关资讯

Gastroenterology:结肠非整倍体检测与结肠癌风险评估

非整倍体检测可以考察结肠低度异型增生的疾病恶化风险

Sci Rep:恶性细胞可通过外泌体传递其恶性特征促进癌症的进展

本研究旨在了解来自高转移细胞系的外泌体是否会影响侵略性较差癌细胞的行为以及血管内皮细胞的特性。结果发现,转移性结肠癌细胞能够通过外泌体将其转移表型传递给同源原代癌细胞,此种形态转变与侵袭性行为更强相关。此外,来源于转移细胞系的外泌体(SW620Exos)导致内皮通透性增高的能力较来源于非转移性细胞系外泌体的能力强(SW480Exos)。基于SWATH定量蛋白质组学分析显示,细胞骨架相关蛋白中SW6

Sci Rep:血浆外泌体miR-125a-3p可作为早期结肠癌的诊断生物标志物

循环系统中外泌体在用于作为疾病的诊断和预后的生物标志物具有极大的潜力。本实验组既往研究中使用miRNA测序识别了异常表达的外泌体miRNA,将其作为结肠癌患者的候选诊断标志物。为验证此发现,本研究纳入了50名早期结肠癌患者和50名匹配的健康志愿者。分离其血浆来源的外泌体miRNA。实时定量PCR显示,早期结肠癌患者血浆外泌体的miR-125a-3p和miR-320c明显升高。ROC曲线显示,曲线下

Gut:影像以及血浆生物标志物用于转移性结肠癌治疗效果的评估

动态增强MRI以及循环DNA检测是预估regorafenib疗效的有效方法,可有效改善患者日常管理,提高治疗效益

Cochrane Db Syst Rev:氟尿嘧啶:口服用药和静脉给药,疗效有区别吗?

氟尿嘧啶类药物是结直肠癌(CRC)治疗的必要组成部分,患者通常更愿意选择口服片剂,因其安全、使用方便,但口服与静脉(IV)剂型的作用真的完全相同吗?这项研究发现CRC无论是治愈性治疗还是姑息性治疗时,IV和口服氟尿嘧啶的作用并不完全相同。

病例讨论:结肠癌肺转移MDT诊疗

一般情况:KPS评分90分,有吸烟史20+年,不规律饮酒史20+年,无高血压、糖尿病、冠心病、慢支等病史